Bladder cancer is a major cause of morbidity, mortality and health-related costs. Urothelial carcinoma is by far the most common histologic type of bladder cancer and may also arise from the upper urinary tract, e.
g renal pelvis and ureter, as well as from the proximal urethra There have been no major advances in the development of new systemic therapies for urothelial carcinoma for over two decades, which may be related to prior lack of profound comprehension of biological pathogenetic mechanisms However, in the last few years there has been a major shift in the development of new promising therapies that stem from improved molecular profiling of this malignancy Developments in molecular biology, genomics, bioinformatics and immunology provide a solid foundation for therapeutic advances A plethora of novel treatment targets and biomarkers are being evaluated, but there has been no molecular biomarker with established clinical utility so far Genomic characterization of each patient's tumor has not been implemented due to the high cost, lack of validated standardized techniques that could be available in different laboratories, as well as absence of validated biomarkers and available therapeutic agents with clinically proven benefit However, genomic characterization before treatment has now started to be implemented in novel clinical trial designs in order to contribute to proper patient selection based on biomarker-based enrichment strategies Several "umbrella" or "basket" type, molecular biomarkers-based trials, in which patient eligibility and/or stratification is based on the presence of specific genetic alterations regardless of tissue of origin and/or histology, are being launched Mathematical models and bioinformatics platforms that perform high level computational integrated pathway analysis may reveal clinical relevant signaling pathways amenable for targeting in individual patient tumors Moreover, the high mutational burden of urothelial carcinoma may create numerous neo-antigens that may explain the very promising results with immune checkpoint inhibitors in early phase clinical trials A combination of several, e g DNA, mRNA, miRNA, protein, and other molecular biomarkers merit further investigation, but this process has to be based on stringent criteria that test and prove clinical utility
Seminars in cancer biology 2015 Aug 22 [Epub ahead of print]
Petros D Grivas, Marilena Melas, Athanasios G Papavassiliou
Taussig Cancer Institute, Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH 44195, USA , USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA , Department of Biological Chemistry, University of Athens, Medical School, 11527 Athens, Greece